ConductScience.org, home

Paper36726367

Triple therapy in COPD: understanding the data.

Suissa S. ERJ Open Res, 2023. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Triple therapy in COPD: understanding the data. Papers, record 36726367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36726367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Triple therapy in COPD: understanding the data.
PubMed
Journal
ERJ Open Res
PubMed
Year
2023
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.91
iCite
Revised in PubMed
2023-02-03
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Suissa SSamyhttps://orcid.org/0000-0002-1281-5296

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133252985Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.Am J Respir Crit Care Med2021https://conductscience.org/library/papers/33252985PubMed
230545959Triple therapy trials in COPD: a precision medicine opportunity.Eur Respir J2018https://conductscience.org/library/papers/30545959PubMed
329669218Making Sense of Triple Inhaled Therapy for COPD.N Engl J Med2018https://conductscience.org/library/papers/29669218PubMed
429668352Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.N Engl J Med2018https://conductscience.org/library/papers/29668352PubMed
536065315Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.Int J Chron Obstruct Pulmon Dis2022https://conductscience.org/library/papers/36065315PubMed
632579807Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.N Engl J Med2020https://conductscience.org/library/papers/32579807PubMed
730091348Single-Inhaler Triple versus Dual Therapy in Patients with COPD.N Engl J Med2018https://conductscience.org/library/papers/30091348PubMed
828642311Run-in bias in randomised trials: the case of COPD medications.Eur Respir J2017https://conductscience.org/library/papers/28642311PubMed
932584168The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.Am J Respir Crit Care Med2020https://conductscience.org/library/papers/32584168PubMed
1010922423Low-dose inhaled corticosteroids and the prevention of death from asthma.N Engl J Med2000https://conductscience.org/library/papers/10922423PubMed
1129429593Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.Lancet2018https://conductscience.org/library/papers/29429593PubMed
1227959688Real-World Evidence - What Is It and What Can It Tell Us?N Engl J Med2016https://conductscience.org/library/papers/27959688PubMed
1335512458
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.
Respir Med2022https://conductscience.org/library/papers/35512458PubMed
1432162970Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med2020https://conductscience.org/library/papers/32162970PubMed
1534569408Triple Therapy in COPD: Time for Adaptive Selection Trials.COPD2021https://conductscience.org/library/papers/34569408PubMed
1630846476Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.Eur Respir J2019https://conductscience.org/library/papers/30846476PubMed
1734126054Perplexing mortality data from triple therapy trials in COPD.Lancet Respir Med2021https://conductscience.org/library/papers/34126054PubMed
1828767357Evidence for Health Decision Making - Beyond Randomized, Controlled Trials.N Engl J Med2017https://conductscience.org/library/papers/28767357PubMed

Download CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42513564Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study.J Clin Med2026https://conductscience.org/library/papers/42513564PubMed
40569182Chronic Obstructive Pulmonary Disease and Inhaled Treatment Effects on Mortality in Patients with Lung Cancer.Ann Am Thorac Soc2025https://conductscience.org/library/papers/40569182PubMed
40391556Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease.J Int Med Res2025https://conductscience.org/library/papers/40391556PubMed
40076807Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions.Int J Mol Sci2025https://conductscience.org/library/papers/40076807PubMed
39191649Emulating randomized trials by observational database studies: the RCT-DUPLICATE initiative in COPD and asthma.Am J Epidemiol2025https://conductscience.org/library/papers/39191649PubMed
39189263The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment.Proteomes2024https://conductscience.org/library/papers/39189263PubMed
38626371Optimizing Pharmacotherapy Management of Chronic Obstructive Pulmonary Disease: Don't Miss the Forest for the Trees.Am J Respir Crit Care Med2024https://conductscience.org/library/papers/38626371PubMed
38397432Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.Biomolecules2024https://conductscience.org/library/papers/38397432PubMed
38337438Comorbidities in COPD: Current and Future Treatment Challenges.J Clin Med2024https://conductscience.org/library/papers/38337438PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36726367

GET https://conductscience.org/api/papers/v1/36726367/authors